WO2023149408A1 - 化粧料組成物、表皮角化細胞増殖用化粧料組成物、表皮角化細胞増殖剤、抗酸化剤、毛乳頭細胞増殖用化粧料組成物、毛乳頭細胞増殖剤、育毛剤、ロリクリン遺伝子発現促進剤、ヘムオキシゲナーゼ－１遺伝子発現促進剤及びコーニファイドエンベロープ形成促進剤 - Google Patents

化粧料組成物、表皮角化細胞増殖用化粧料組成物、表皮角化細胞増殖剤、抗酸化剤、毛乳頭細胞増殖用化粧料組成物、毛乳頭細胞増殖剤、育毛剤、ロリクリン遺伝子発現促進剤、ヘムオキシゲナーゼ－１遺伝子発現促進剤及びコーニファイドエンベロープ形成促進剤 Download PDF

Info

Publication number
WO2023149408A1
WO2023149408A1 PCT/JP2023/002956 JP2023002956W WO2023149408A1 WO 2023149408 A1 WO2023149408 A1 WO 2023149408A1 JP 2023002956 W JP2023002956 W JP 2023002956W WO 2023149408 A1 WO2023149408 A1 WO 2023149408A1
Authority
WO
WIPO (PCT)
Prior art keywords
euglena
derived
cosmetic composition
culture supernatant
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/002956
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
光祐 安田
由布子 三輪
綾香 中島
崇 安藤
健吾 鈴木
景太 福本
純子 津田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euglena Co Ltd
Original Assignee
Euglena Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euglena Co Ltd filed Critical Euglena Co Ltd
Priority to JP2023578548A priority Critical patent/JPWO2023149408A1/ja
Publication of WO2023149408A1 publication Critical patent/WO2023149408A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Definitions

  • the present invention provides a cosmetic composition, a cosmetic composition for proliferating epidermal keratinocytes, an agent for proliferating epidermal keratinocytes, an antioxidant, a cosmetic composition for proliferating dermal papilla cells, an agent for proliferating dermal papilla cells, a hair restorer,
  • the present invention relates to a loricrin gene expression promoter, a heme oxygenase-1 gene expression promoter and a cornified envelope formation promoter.
  • Patent Document 1 describes a cosmetic containing, as an active ingredient, a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglenoids.
  • Patent Document 2 describes an animal cell culture growth promoter containing, as an active ingredient, culture supernatant of embryonic membranes derived from fertilized eggs of birds or reptiles.
  • An object of the present invention is to provide a cosmetic composition, a cosmetic composition for proliferation of epidermal keratinocytes, an agent for proliferation of epidermal keratinocytes, an antioxidant, a cosmetic composition for proliferation of dermal papilla cells, an agent for proliferation of dermal papilla cells, and a hair restorer.
  • agent a loricrin gene expression promoter, a heme oxygenase-1 gene expression promoter, and a cornified envelope formation promoter.
  • the above problems are solved by a cosmetic composition containing a Euglena-derived substance and an animal cell-derived culture supernatant.
  • the above-mentioned problems are solved by a cosmetic composition for epidermal keratinocyte proliferation containing a Euglena-derived substance and a culture supernatant of embryonic membranes derived from avian fertilized eggs.
  • the above problems are solved by an epidermal keratinocyte proliferating agent containing a Euglena-derived substance and a culture supernatant of embryonic membranes derived from avian fertilized eggs.
  • the above problems are solved by an antioxidant containing a Euglena-derived substance and a culture supernatant of embryonic membranes derived from avian fertilized eggs.
  • the above problems are solved by a cosmetic composition for dermal papilla cell proliferation containing a Euglena-derived substance and an animal cell-derived culture supernatant.
  • the above problems are solved by a dermal papilla cell proliferation agent containing a Euglena-derived substance and an animal cell-derived culture supernatant.
  • the above problems are solved by a hair restorer containing a Euglena-derived substance and an animal cell-derived culture supernatant.
  • the above problems are solved by a loricrin (LOR) gene expression promoter containing a Euglena-derived substance and a culture supernatant of embryonic membranes derived from avian fertilized eggs.
  • heme oxygenase-1 HMOX1
  • HMOX1 heme oxygenase-1
  • a cornified envelope formation promoter containing a Euglena-derived substance and a culture supernatant of embryonic membranes derived from avian fertilized eggs.
  • the Euglena-derived substance is preferably an aqueous solvent extract of Euglena or a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.
  • the culture supernatant is preferably a culture supernatant of embryonic membranes derived from fertilized avian eggs.
  • the culture supernatant is preferably the supernatant of chicken extraembryonic membrane cell conditioned medium.
  • a cosmetic composition capable of maintaining skin condition, a cosmetic composition for epidermal keratinocyte proliferation, an epidermal keratinocyte proliferation agent, an antioxidant, and a cosmetic for dermal papilla cell proliferation
  • a composition, dermal papilla cell proliferation agent, hair restorer, loricrin gene expression promoter, heme oxygenase-1 gene expression promoter, and cornified envelope formation promoter can be provided.
  • Fig. 4 is a graph showing proliferation of human epidermal keratinocytes when various raw materials were added (***p ⁇ 0.001, **p ⁇ 0.01, t-test (Bonferroni correction) vs. control).
  • 1 is a graph showing the results of loricrin (LOR) gene expression analysis.
  • FIG. 10 is a graph showing the results of heme oxygenase (HMOX1) gene expression analysis.
  • HMOX1 heme oxygenase
  • FIG. The present embodiment provides a cosmetic composition, a cosmetic composition for epidermal keratinocyte proliferation, and an epidermal keratinocyte proliferation agent containing a Euglena-derived substance and a culture supernatant of an embryonic membrane derived from avian fertilized eggs.
  • antioxidant cosmetic composition for dermal papilla cell proliferation, dermal papilla cell proliferation agent, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter and cornified envelope formation promoter It relates to agents.
  • the term “euglena” includes microorganisms taxonomically classified into the genus Euglena, variants thereof, variants thereof, and closely related species of the family Euglenaceae.
  • the genus Euglena is a group of eukaryotic organisms belonging to Excoverta, Euglenozoa, Euglenomycetes, Euglenoides, and Euglenaceae.
  • Euglena chadefaudii Euglena deses, Euglena gracilis, Euglena granulata, Euglena mutabilis, Euglena proxima, Euglena spirogyra, and Euglena viridis.
  • Euglena gracilis particularly E. gracilis Z strain can be used, but in addition, Euglena gracilis Z strain mutant strain SM-ZK strain (chloroplast-deficient strain), variants of E. gracilis var.
  • the genus Euglena is widely distributed in freshwater such as ponds and marshes, and it may be used by separating it from these, or any already isolated Euglena genus may be used.
  • the genus Euglena includes all its variants. These mutant strains also include those obtained by genetic methods such as recombination, transduction, and transformation.
  • Euglenoid algae can be used as Euglena.
  • Euglenoid cells separated by centrifugation, filtration, sedimentation, or the like can be used as they are as Euglenoid alga bodies.
  • Euglena living cells can be used as they are after being harvested from the culture vessel, but they are preferably washed with water or physiological saline.
  • the Euglenoid alga body may be used in the form of a dispersion in a liquid such as water.
  • a mechanically processed product of algal bodies obtained by subjecting living Euglena cells to ultrasonic irradiation treatment or mechanical treatment such as homogenization may be used as Euglena algal bodies.
  • a dried mechanically processed product obtained by subjecting a mechanically processed product to a drying treatment may be used as the Euglenoid algal body.
  • Euglena extract In the present embodiment, it is possible to use an Euglena extract (Euglena extract) as Euglena, and it is particularly preferable to use an Euglena aqueous solvent extract.
  • Euglena aqueous solvent extract means an extract extracted from Euglena using an aqueous solvent. It is preferable to use a water extract, a hot water extract, an alcohol extract, or a glycol extract of Euglena extracted for several seconds to several tens of hours at °C.
  • the water used for extraction does not necessarily have to be distilled, pure, or ultrapure water, and may, for example, be tap water or contain impurities, but may contain components that interfere with the extraction of the active ingredient. Free water is preferred.
  • water extract means an extract with water at 0 to 50°C (excluding 0°C).
  • water means water at 0 to 50°C (excluding 0°C).
  • the temperature of the water is not particularly limited as long as the active ingredient can be sufficiently extracted without affecting the active ingredient. Especially preferred is 10 to 30°C.
  • the "hot water extract” means an extract with water at a temperature higher than 50°C, and can also be called a “hot water extract”.
  • hot water means water having a temperature higher than 50° C., and is a concept that includes “hot water”, including water in a boiling state. Moreover, it is not limited to hot water in a liquid state, but also includes hot water in a gaseous state and a supercritical state.
  • the temperature of the hot water is not particularly limited as long as the active ingredient can be extracted sufficiently without affecting the active ingredient. °C and 100°C or less.
  • the pH of the water used for extraction is not particularly limited as long as the active ingredient can be sufficiently extracted without affecting the active ingredient, preferably pH 4 to 10, more preferably pH 5 to 9. , particularly preferably pH 6-8.
  • aqueous solvent one or more solvents that can sufficiently extract the active ingredient without affecting the active ingredient and that can be used for extraction are usually selected.
  • examples include, but are not limited to, water, alcohols, glycols, and the like.
  • Alcohols include ethanol, methanol, n-propanol, isopropanol and the like.
  • Glycols include 1,3-butylene glycol (BG) and propylene glycol.
  • Other aqueous solvents include acetone and the like. These solvents may be used alone or as an aqueous solution, or may be used as a mixed solvent of any two or three or more.
  • the temperature of the aqueous solvent used for extraction is, for example, 0°C or higher, and is not particularly limited as long as it does not affect the active ingredients.
  • Aqueous solvents in a boiling or supercritical state can also be used, but it is preferred to use aqueous solvents at 5°C to 600°C, more preferably 10°C to 200°C. Therefore, the aqueous solvent for extraction includes an aqueous solvent in a boiling state or a supercritical state.
  • the amount of the aqueous solvent used for extraction is preferably an amount that can sufficiently dissolve the water-soluble active ingredient contained in Euglena.
  • the extraction method is also not particularly limited.
  • extraction can be performed by the method shown below, but it is not limited to this, and a normal extraction method can be freely selected and used.
  • a dry powder of Euglena algae is immersed in an aqueous solvent for a predetermined period of time and then centrifuged or filtered, or a dry powder of Euglena algae is added to an aqueous solvent and shaken to uniformly disperse, followed by centrifugation or filtration. method, etc.
  • Euglena can be extracted with water by the usual method shown below, but it is not limited to this.
  • the Euglena tissue and water are placed in a container and allowed to stand for a predetermined period of time with appropriate stirring or shaking, and the obtained extract can be used as a water extract as it is.
  • the supernatant obtained by centrifuging such an extract can also be used as an aqueous extract.
  • such an extract or supernatant can be concentrated and dried to remove water and used as an aqueous extract.
  • the water extraction may be carried out by adding a small amount of alcohol, preferably ethanol, to water in an amount of, for example, 10% by mass or less, in order to increase the extraction efficiency and shorten the extraction time.
  • the extraction time for water extraction is not particularly limited as long as the active ingredient is extracted, and can be appropriately set in the range of several seconds to several tens of hours depending on the extraction temperature.
  • the extraction with hot water can be performed by a commonly used method as shown below, but it is not limited to this.
  • Euglena is introduced into a commonly used extractor together with water, it is extracted by heating.
  • the pressure during extraction can be set to 1 to 5000 atmospheres, preferably 60 to 400 atmospheres.
  • the extraction time is short, for example, preferably within 3 minutes, more preferably within 1 minute, and particularly preferably within 30 seconds.
  • the extracted Euglena extract can be used as it is for the epidermal keratinocyte proliferation agent according to the present embodiment, the cosmetic composition for dermal papilla cell proliferation, the dermal papilla cell proliferation agent, the hair restorer, the loricrin gene expression promoter, and the heme oxygenase-1.
  • the extract is further subjected to an appropriate separation means (e.g., partition extraction, gel filtration, silica gel chromatography, reverse phase or normal phase). It is also possible to fractionate and use a highly active fraction by high-performance liquid chromatography, etc.).
  • the Euglena extract or a fraction thereof can be concentrated and dried to remove the aqueous solvent, and this can be used as an aqueous solvent extract.
  • an extract extracted using BG may be used as the Euglena extract.
  • the Euglena extract may be in the form of a complex with other cosmetic raw materials, such as permeation type collagen, permeation type elastin, permeation type hyaluronic acid, and hexapeptide-33 in a multi-layered capsule.
  • Euglena extract a water-soluble component extracted by enzymatically decomposing algal cells belonging to the genus Euglena, specifically, a hydrolyzed Euglena extract obtained by enzymatically hydrolyzing and extracting Euglena powder (Euglena algae body) is used.
  • can be Hydrolyzed Euglena extract can be prepared according to the method described in JP-A-2010-90065.
  • Purified water is preferably added in an amount (weight) 100 times the amount (weight) of the dried Euglena, and pressure and heat treatment is performed. After that, a proteolytic enzyme is added to treat the algal body. After completion of the treatment, it is deactivated, for example, at 90° C., and the residue and water-soluble components are separated by centrifugation or filtration.
  • the pressure and heat treatment conditions are preferably 100 to 150 ° C. using an autoclave, atmospheric pressure to 0.255 MPa, and heat and pressure treatment for 1 minute to 30 minutes. It is preferable to heat and pressurize at 0.14 MPa and 121° C. for 10 minutes.
  • the proteolytic enzyme for example, pepsin, pancreatin, papain, and other commonly used enzymes having protease activity may be used alone or in combination. It is preferred to employ an endo-type peptidase to decompose into .
  • Pantidase MP and Alloase AP-10 manufactured by Yakult Pharmaceutical Co., Ltd. can also be used.
  • the concentration of the enzyme added, the pH and reaction temperature of the reaction solution, and other conditions may be selected optimally for each enzymatic agent.
  • the water-soluble component obtained in this way can be used as it is, but it can also be used after undergoing purification operations such as fractionation, deodorization, decolorization, and concentration within the range that does not lose the effect of the present invention.
  • Polymer is a porous polymer ( ⁇ -1,3-glucan) in which about 700 glucoses are polymerized by ⁇ -1,3-bonds, and is a storage polysaccharide contained in the genus Euglena. is. Paramylon particles are flattened spheroidal particles and are formed by helically intertwined ⁇ -1,3-glucan chains.
  • Paramylon exists as granules in the Euglena cells of all species and varieties, and the number, shape, and uniformity of the particles are characteristic for each species.
  • Paramylon is composed only of glucose, and the average degree of polymerization of paramylon obtained from E. gracilis Z wild strain and chloroplast-deficient strain SM-ZK is about 700 glucose units.
  • Paramylon is insoluble in water and hot water, but soluble in dilute alkali, strong acid, dimethyl sulfoxide, formaldehyde and formic acid.
  • the average density of paramylon is 1.53 for E. gracilis Z and 1.63 for E. gracilis var. bacillaris SM-L1.
  • paramylon has a gentle helical structure in which three straight-chain ⁇ -1,3-glucans are twisted like a right-handed rope. Several of these glucan molecules aggregate to form paramylon granules. Paramylon granules have a very large crystal structure portion, accounting for about 90%, and are compounds with the highest crystal structure rate among polysaccharides (Euglena, Physiology and Biochemistry, edited by Shozaburo Kitaoka, Gakkai Shuppan Center). The particle size distribution of paramylon (manufactured by Euglena Co., Ltd.) has a median diameter of 1.5 to 2.5 ⁇ m when measured with a laser diffraction/scattering particle size distribution analyzer.
  • Paramylon particles are isolated from cultured Euglena cells by any appropriate method and purified into fine particles, and are usually provided as powder.
  • paramylon particles can be (1) cultured Euglena cells in any appropriate medium, (2) separation of Euglena cells from the medium, (3) isolation of paramylon from the separated Euglena cells, ( 4) purification of the isolated paramylon, and optionally (5) cooling and subsequent lyophilization. Isolation of paramylon is performed, for example, using non-ionic or anionic detergents of the type that are largely biodegradable. Purification of paramylon occurs substantially simultaneously with isolation.
  • Processed products of paramylon include water-soluble paramylon obtained by chemically or physically treating paramylon by various known methods, sulfated paramylon, and paramylon derivatives.
  • Examples of processed products of paramylon include amorphous paramylon and emulsion paramylon.
  • Amorphous paramylon is a substance obtained by amorphizing crystalline paramylon derived from Euglena.
  • Amorphous paramylon has a relative crystallinity of 1 to 20% with respect to crystalline paramylon produced from Euglena by a known method. However, this relative crystallinity is obtained by the method described in JP-A-2011-184592.
  • amorphous paramylon and paramylon were each pulverized with a pulverizer (ball mill MM400 manufactured by Retsh) for 5 minutes at a frequency of 20 times/second, and then analyzed using an X-ray diffractometer (H'PertPRO manufactured by Spectris).
  • H'PertPRO manufactured by Spectris
  • Amorphous paramylon is prepared according to the method described in JP-A-2011-184592 by treating crystalline paramylon powder with an alkali, then neutralizing it with an acid, followed by washing, removing water, and drying.
  • Processed products of paramylon also include water-soluble paramylon obtained by chemically or physically treating paramylon by various known methods, sulfated paramylon, and paramylon derivatives.
  • Embodision paramylon is a substance also called emulsion paramylon because its processing method and physical properties are similar to emulsions, and is obtained by adding water to paramylon according to the method described in JP-A-2016-199650. It is processed paramylon that is swollen by bonding with water four times or more, obtained by performing a collision treatment in which the fluid is ejected from a fine nozzle at an ultrahigh pressure to collide with an object to be collided.
  • Emulsion paramylon is a known physical property modification device that ejects a slurry obtained by adding a water-soluble solvent to a solid such as powder at an ultrahigh pressure from a fine-pore nozzle to collide with an object to be collided (for example, JP-A-2011-88108). It can be obtained by performing collision treatment one or more times at a nozzle pressure of 245 MPa at the time of jetting using a device described in Japanese Patent Application Laid-Open No. 6-47264.
  • Emulsion paramylon has a median diameter of 5 times or more that of paramylon and 7 ⁇ m or more when the particle size is measured with a laser diffraction/scattering particle size distribution analyzer, and the particles are separated from adjacent particles by an optical electron microscope. Adhesion was observed, and it swelled by binding with water four times or more that of paramylon.
  • Slurry which is a mixture of raw material paramylon and water, is a free-flowing fluid. It has excellent stickiness and elasticity, and has a paste-like feel.
  • the processed paramylon obtained is called emulsion paramylon in this specification because of its processing method and physical properties, but it is unknown whether or not it is emulsified. is.
  • Cosmetic composition of the present embodiment cosmetic composition for epidermal keratinocyte proliferation, epidermal keratinocyte proliferation agent, cosmetic composition for dermal papilla cell proliferation, dermal papilla cell proliferation agent, hair restorer, loricrin (LOR)
  • the gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter contain the culture supernatant of avian egg embryo membrane (animal cell-derived culture supernatant) as an active ingredient.
  • Examples of birds from which embryonic membranes are collected include quails, chickens, and the like, but are not limited to these, and any avian animal having egg embryonic membranes may be used.
  • embryonic membrane means a membranous tissue that is formed outside the embryo during the development process of birds, performs functions such as protection, nutrition, and respiration of the embryo, and does not participate in the construction of the body after hatching or birth.
  • the outermost chorion of the embryo the amniotic membrane that envelops the embryo body, the allantois that forms the allantois, the chorioallantoic membrane (CAM) that partially adheres to the chorion and the allantoic membrane, and the yolk that envelops the yolk. Sac etc. are mentioned.
  • the embryonic membrane culture supernatant is the medium in which the embryonic membrane is isolated and cultured.
  • Embryonic membranes to be cultured may be one of the above-described serous membranes, amniotic membranes, allantoic membranes, allantoic membranes, yolk sacs, or the like, or may be cultured by mixing a plurality of types.
  • the embryonic membrane can be collected from the egg by a known method.
  • embryonic membranes can be isolated by the following method. First, a fertilized egg is incubated under conditions suitable for artificial incubation for a predetermined period of time, and then the eggshell is cracked. (2) the amniotic membrane can be obtained by removing the transparent membranous tissue that does not have blood vessels running around the fetus; (4) the serosa can be obtained by removing the outermost membranous tissue surrounding all elements within the egg; Furthermore, with longer incubation times, the chorioallantoic membrane partially fuses with the allantoic membrane to form the chorioallantoic membrane.
  • the chorioallantoic membrane can be obtained by removing the membranous tissue that is in contact with the eggshell and has blood vessels running through it.
  • the incubation period may be appropriately determined depending on each animal and the target membrane tissue. For example, in the case of chicken eggs, 4 to 21 days is preferable, 10 to 18 days is more preferable, and 13 to 13 days is preferable. 15 days is more preferred.
  • these embryonic membranes When these embryonic membranes are cultured, they may be cultured as they are in a membranous state. Alternatively, embryonic membrane-derived cells may be isolated and cultured from the embryonic membrane.
  • a medium generally used for culturing animal cells can be used, and examples thereof include, but are not limited to, DMEM and F12. Supplements that are usually blended as medium additives may be added to this medium.
  • the conditions used for normal animal cell culture can be used, typically using a carbonate buffer-based medium and culturing at 5% CO 2 at 37° C.
  • the culture conditions are as follows. is not limited to, and can be appropriately selected by those skilled in the art.
  • the culture time is not particularly limited, but preferably 1 to 7 days, more preferably 2 to 6 days.
  • the supernatant may be collected and added to the cell culture medium as it is, or a medium obtained by removing solids such as cell debris by filtration or centrifugation may be added. good.
  • the amount of the culture supernatant added to the cell culture medium is not particularly limited as long as it is an effective amount at which the growth effect of cultured cells is observed, but the final concentration in the medium is preferably 20% or more, more preferably 35% or more. , more preferably 50% or more.
  • the epidermal keratinocyte proliferation agent contains a Euglena-derived substance and a culture supernatant of an embryonic membrane derived from avian fertilized eggs, and is used to promote the proliferation of epidermal keratinocytes. It is.
  • the dermal papilla cell proliferation agent contains a Euglena-derived substance and a culture supernatant of embryonic membrane derived from avian fertilized eggs, and is used to promote the proliferation of dermal papilla cells. be.
  • the hair restorer according to the present embodiment contains a Euglena-derived substance and a culture supernatant of an embryonic membrane derived from avian fertilized eggs, and is used to promote hair growth through its effect of promoting proliferation of dermal papilla cells. It is.
  • the loricrin (LOR) gene expression promoter contains a Euglena-derived substance and a culture supernatant of an embryonic membrane derived from avian fertilized eggs, and promotes loricrin (LOR) gene expression. It is used for “Promote gene expression” includes not only expression at the transcription level (expression as mRNA) but also expression at the translation level (expression as protein).
  • Lochlorin is a hydrophobic protein rich in glycine, serine, cysteine, etc.
  • Lochlorin is the major constituent of the cornified envelope. After the base of the cornified envelope is formed in the keratinocyte membrane by involucrin, cystatin A, etc., a firm cornified envelope is formed while loricrin bridges.
  • the cornified envelope is a proteinous membranous structure that envelops the corneocytes that make up the outermost layer of the skin.
  • the cornified envelope is an organelle that plays a major role in the stratum corneum barrier function.
  • the cornified envelope formation promoter contains a Euglena-derived substance and a culture supernatant of embryonic membranes derived from avian fertilized eggs, and is used to promote the formation of cornified envelopes in keratin. It is something that can be done.
  • Heme oxygenase-1 (HMOX1) gene expression promoter contains a Euglena-derived substance and a culture supernatant of an embryonic membrane derived from avian fertilized eggs, and the heme oxygenase-1 (HMOX1) gene is used to promote the expression of “Promote gene expression” includes not only expression at the transcription level (expression as mRNA) but also expression at the translation level (expression as protein).
  • Heme oxygenase-1 is an enzyme responsible for degrading heme, and its expression is induced when cells are exposed to reactive oxygen species or heavy metals, and exhibits antioxidant activity and cytoprotection.
  • the antioxidant according to the present embodiment contains a Euglena-derived substance and a culture supernatant of avian fertilized egg-derived embryonic membranes.
  • Target cells are not particularly limited, but eukaryotic cells are exemplified. Examples of cells include skin-related cells such as keratinocytes (keratinocytes), epithelial cells, fibroblasts, and dermal papilla cells, but other cells may also be used.
  • skin-related cells such as keratinocytes (keratinocytes), epithelial cells, fibroblasts, and dermal papilla cells, but other cells may also be used.
  • the epidermal keratinocyte proliferation agent, dermal papilla cell proliferation agent, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter are It is configured as a food composition such as a cosmetic composition, a pharmaceutical composition, and a health food, and is preventively used, administered, ingested, and administered in order to maintain the skin condition.
  • the epidermal keratinocyte proliferation agent, dermal papilla cell proliferation agent, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter are Epidermal keratinocyte proliferative action, dermal papilla cell proliferative action, hair growth action, loricrin (LOR) gene expression promotion action, heme oxygenase-1 (HMOX1) gene expression promotion action and cornified envelope formation promotion action are used to produce cosmetics. It can be suitably used for the composition.
  • the cosmetic composition can be applied to any form of cosmetics.
  • skin care cosmetics such as cleansing agents, facial cleansers, lotions, lotions, milky lotions, creams, serums, packs, and scrubs, foundations, concealers, makeup bases, lipsticks, blushers, eyeshadows, eyeliners, hair growth lotions, It can be applied to shampoos, treatments, makeup cosmetics such as eyelash serums, sunscreen cosmetics, and the like.
  • the cosmetic composition according to the present embodiment includes the epidermal keratinocyte proliferation agent, the dermal papilla cell proliferation agent, the hair restorer, the loricrin (LOR) gene expression promoter, and the heme oxygenase-1 (HMOX1) gene according to the present embodiment.
  • the expression enhancer and the cornified envelope formation enhancer it is possible to freely select and blend one or two or more components that are commonly used in cosmetic compositions.
  • base materials preservatives, emulsifiers, coloring agents, preservatives, surfactants, ultraviolet absorbers, antioxidants, moisturizing agents, ultraviolet absorbers, fragrances, antiseptic antifungal agents, extender pigments, coloring pigments, alcohols, All additives that can normally be used in the cosmetic field, such as water, can be included.
  • an epidermal keratinocyte proliferation agent a dermal papilla cell proliferation agent, a hair restorer, a loricrin (LOR) gene expression promoter, a heme oxygenase-1 (HMOX1) gene expression promoter, and cornified
  • the content of the enveloping promoter is not particularly limited, and can be freely set according to the purpose.
  • the epidermal keratinocyte proliferation agent, dermal papilla cell proliferation agent, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter of the present embodiment are pharmaceuticals.
  • the epidermal keratinocyte proliferation agent, dermal papilla cell proliferation, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter of the present embodiment are pharmaceuticals. in the field of epidermal keratinocyte proliferation, dermal papilla cell proliferation, hair growth, loricrin (LOR) gene expression promotion, heme oxygenase-1 (HMOX1) gene expression promotion and cornified envelope formation promotion.
  • a pharmaceutical composition having the effect is provided by adding a pharmaceutically acceptable carrier and additives together with a sufficient amount of Euglena-derived substance and culture supernatant of embryonic membrane derived from avian fertilized eggs.
  • the pharmaceutical composition may be a drug or a quasi-drug.
  • the pharmaceutical composition may be applied internally or externally. Therefore, the pharmaceutical composition is used in the form of an oral preparation, an injection such as an intravenous injection, a subcutaneous injection, an intradermal injection, an intramuscular injection and/or an intraperitoneal injection, a transmucosal application, a transdermal application, and the like. be able to.
  • the dosage form of the pharmaceutical composition can be appropriately set depending on the application form. Semi-solid formulations such as ointments or gels are included.
  • the pharmaceutical composition according to the present embodiment can contain one or more pharmaceutically acceptable additives that are freely selected.
  • pharmaceutically acceptable additives that are freely selected.
  • excipients for example, excipients, binders, disintegrants, surfactants, preservatives, coloring agents, flavoring agents, fragrances, stabilizers, preservatives
  • a drug delivery system can be used to prepare a sustained-release preparation or the like.
  • the epidermal keratinocyte proliferation agent, dermal papilla cell proliferation agent, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter of the present embodiment are foods.
  • the epidermal keratinocyte proliferation agent, dermal papilla cell proliferation, hair restorer, loricrin (LOR) gene expression promoter, heme oxygenase-1 (HMOX1) gene expression promoter, and cornified envelope formation promoter of the present embodiment are foods.
  • loricrin (LOR) gene expression promoter heme oxygenase-1 (HMOX1) gene expression promotion
  • cornified envelope formation promotion are foods.
  • the present invention can provide a food composition for a food labeled as for epidermal keratinocyte proliferation or the like in the field of foods.
  • the food composition include general foods, foods for specified health uses, foods with nutrient function claims, foods with function claims, foods for hospital patients, supplements, and the like. It can also be used as a food additive.
  • Examples of the food composition include seasonings, processed meat products, processed agricultural products, beverages (lactic acid beverages, soft drinks, alcoholic beverages, carbonated beverages, milk beverages, fruit juice beverages, tea, coffee, nutritional drinks, etc.), powders Beverages (powdered juice, powdered soup, etc.), concentrated drinks, confectionery (candies, cookies, biscuits, gums, gummies, chewables, tablets, chocolate, etc.), breads, cereals and the like.
  • the shape may be capsule, troche, syrup, granule, powder, or the like.
  • Foods for Specified Health Uses are foods that contain functional health ingredients that affect physiological functions, etc., and can be labeled as suitable for specific health uses with the permission of the Director-General of the Consumer Affairs Agency. be. In the present invention, it is a food product that is marketed with an indication of a specific health use related to proliferation of epidermal keratinocytes.
  • a food with nutrient function claims is a food that is used to supplement nutritional ingredients (vitamins, minerals), and that displays the functions of the nutritional ingredients.
  • nutritional ingredients vitamins, minerals
  • the amount of nutrients contained in the recommended daily intake must be within the specified upper and lower limits. also need to
  • Foods with functional claims are foods labeled with functionalities based on scientific evidence under the responsibility of the business operator. Information on the grounds for safety and functionality was submitted to the Commissioner of the Consumer Affairs Agency before sales.
  • the food composition according to the present embodiment in addition to the Euglena-derived substance and the culture supernatant of embryonic membrane derived from avian fertilized eggs, one or more components that can be used in normal food compositions are added. It is possible to freely select and blend them. For example, all additives commonly used in the food field, such as various seasonings, preservatives, emulsifiers, stabilizers, flavoring agents, coloring agents, preservatives, and pH adjusters, can be contained.
  • Example 1 Hydrolyzed Euglena extract> As Sample 1, a hydrolyzed Euglena extract, which is a water-soluble component extracted by proteolytic decomposition of Euglena gracilis cells, was used. The hydrolyzed Euglena extract is obtained by adding 100 times the amount of purified water to 1 g of Euglena gracilis powder (Euglena algae, manufactured by Euglena Co., Ltd.), heating to a pressure of 0.1 MPa and a temperature of 12 ° C., and heating and pressurizing for 10 minutes. processed.
  • Euglena gracilis powder Euglena algae, manufactured by Euglena Co., Ltd.
  • Example 2 Euglena extract (Euglena extract EX)> As Sample 2, an Euglena extract was used.
  • the Euglena extract was prepared using Euglena gracilis powder (Euglena algal body, manufactured by Euglena Co., Ltd.) as a raw material and 1,3-butylene glycol (BG) as a solvent.
  • Euglena gracilis powder Euglena algal body, manufactured by Euglena Co., Ltd.
  • BG 1,3-butylene glycol
  • Example 3 Chick egg extraembryonic membrane cell conditioned medium (cerament)> As sample 3, a chicken egg-derived cell culture supernatant (trade name: CELLAMENT (registered trademark), Integriculture Co., Ltd.) was used. The egg-derived cell culture supernatant contains 75% chicken egg extraembryonic membrane cell conditioned medium, 20% BG, and 5% pentylene glycol.
  • sample 4 Euglena serum formulation was prepared by combining the hydrolyzed Euglena extract of sample 1, the Euglena extract of sample 2 (Euglena extract EX), and the chick extraembryonic membrane cell conditioned medium (cerament) of sample 3.
  • Test 1 Proliferation of human epidermal keratinocytes>
  • proliferation of human epidermal keratinocytes by the Euglena-cerament formulation (Sample 4) was evaluated.
  • RNA change analysis using next-generation sequencer> human epidermal keratinocytes (2.5 ⁇ 10 4 cells/well) were seeded in a 12-well plate using HuMedia-KG2 medium (growth medium). Next, the Euglena-cerament formulation (Sample 4) was dissolved in HuMedia-KB2 medium (non-proliferation medium), and the medium was replaced. After replacing the medium, the cells were cultured for 3 days, the culture supernatant was removed, and total RNA was isolated from the cells using RNAiso Plus, followed by purification using NucleoSpin (registered trademark) RNA.
  • HuMedia-KB2 medium non-proliferation medium
  • Enrichment analysis was performed on the variable genes whose expression level was increased by the euglena serum prescription, and it was found that autocrine signaling (hormones and chemical messengers secreted by cells act on the cells themselves), nuclear receptors meta-pathway (Nuclear receptors meta-pathway; pathway related to receptors that cause activation or suppression of transcription of DNA in the nucleus), estrogen signaling pathway (Estrogen signaling pathway), hair follicle development: It was found that gene clusters such as cytodifferentiation, aging, and skin development are included.
  • ⁇ Test 3 Formation of cornified envelope and analysis of antioxidant-related genes>
  • Euglena-cerament formulation (Sample 4), hydrolyzed Euglena extract alone (Sample 1), Euglena extract EX alone (Sample 2), and Cerament alone (Sample 3) were added and cultured. Genetic changes were comprehensively analyzed using a generational sequencer.
  • RNA was reverse transcribed to synthesize cDNA, and the gene expression level was evaluated by real-time PCR.
  • Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal standard for real-time PCR.
  • the gene expression level of loricrin (LOR), which is the main component of the cornified envelope increased about 4-fold in the serum formulation compared to the control cultured without adding anything (Fig. 2).
  • HMOX1 heme oxygenase-1
  • an antioxidant enzyme increased approximately twice in the serum formulation compared to the control (Fig. 3).
  • the Euglena serum formulation may promote the proliferation of human epidermal keratinocytes, and may be effective in the formation of cornified envelopes and antioxidants.
  • Euglena-derived substances as active ingredients in combination with the culture supernatant of embryonic membranes derived from avian fertilized eggs, it is possible to promote the growth of human epidermal keratinocytes, promote the formation of cornified envelopes, It was shown that the antioxidative action can be effectively exhibited.
  • Test 4 Proliferation of human dermal papilla cells> In Test 4, the proliferation of human dermal papilla cells by the Euglena serum formulation (Sample 4) was evaluated.
  • Example 4 (Method of Test 4) Euglena serum formulation (sample 4), hydrolyzed euglena extract alone (sample 1), euglena extract EX alone (sample 2), and serum alone (sample 3) were added to human dermal papilla cells (4,000 cells/well/100 uL). The cells were added, cultured for 3 days, and the number of cells was measured using Cell Counting Kit-8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2023/002956 2022-02-02 2023-01-31 化粧料組成物、表皮角化細胞増殖用化粧料組成物、表皮角化細胞増殖剤、抗酸化剤、毛乳頭細胞増殖用化粧料組成物、毛乳頭細胞増殖剤、育毛剤、ロリクリン遺伝子発現促進剤、ヘムオキシゲナーゼ－１遺伝子発現促進剤及びコーニファイドエンベロープ形成促進剤 Ceased WO2023149408A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023578548A JPWO2023149408A1 (enExample) 2022-02-02 2023-01-31

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-015147 2022-02-02
JP2022015147 2022-02-02

Publications (1)

Publication Number Publication Date
WO2023149408A1 true WO2023149408A1 (ja) 2023-08-10

Family

ID=87552388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/002956 Ceased WO2023149408A1 (ja) 2022-02-02 2023-01-31 化粧料組成物、表皮角化細胞増殖用化粧料組成物、表皮角化細胞増殖剤、抗酸化剤、毛乳頭細胞増殖用化粧料組成物、毛乳頭細胞増殖剤、育毛剤、ロリクリン遺伝子発現促進剤、ヘムオキシゲナーゼ－１遺伝子発現促進剤及びコーニファイドエンベロープ形成促進剤

Country Status (2)

Country Link
JP (1) JPWO2023149408A1 (enExample)
WO (1) WO2023149408A1 (enExample)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010090065A (ja) * 2008-10-08 2010-04-22 Nihon Kolmar Co Ltd 化粧料
JP2017155195A (ja) * 2016-03-04 2017-09-07 第一工業製薬株式会社 パラミロン水性分散液及び細胞増殖促進剤
JP2020040996A (ja) * 2017-05-02 2020-03-19 剛士 田邊 医薬品組成物及び化粧品組成物
KR102096263B1 (ko) * 2018-12-12 2020-04-02 고려대학교 산학협력단 자연적으로 발생한 유글레나 그라실리스 돌연변이체를 이용한 파라밀론 생산
WO2020096004A1 (ja) * 2018-11-08 2020-05-14 インテグリカルチャー株式会社 動物細胞増殖促進剤、動物細胞培養用培地及び動物細胞培養装置
JP2020094013A (ja) * 2018-12-14 2020-06-18 株式会社神鋼環境ソリューション 細胞賦活化剤
JP2020127398A (ja) * 2019-02-07 2020-08-27 株式会社神鋼環境ソリューション サーチュイン発現量増進剤
JP2021120398A (ja) * 2018-11-07 2021-08-19 剛士 田邊 医薬品組成物及び化粧品組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010090065A (ja) * 2008-10-08 2010-04-22 Nihon Kolmar Co Ltd 化粧料
JP2017155195A (ja) * 2016-03-04 2017-09-07 第一工業製薬株式会社 パラミロン水性分散液及び細胞増殖促進剤
JP2020040996A (ja) * 2017-05-02 2020-03-19 剛士 田邊 医薬品組成物及び化粧品組成物
JP2021120398A (ja) * 2018-11-07 2021-08-19 剛士 田邊 医薬品組成物及び化粧品組成物
WO2020096004A1 (ja) * 2018-11-08 2020-05-14 インテグリカルチャー株式会社 動物細胞増殖促進剤、動物細胞培養用培地及び動物細胞培養装置
KR102096263B1 (ko) * 2018-12-12 2020-04-02 고려대학교 산학협력단 자연적으로 발생한 유글레나 그라실리스 돌연변이체를 이용한 파라밀론 생산
JP2020094013A (ja) * 2018-12-14 2020-06-18 株式会社神鋼環境ソリューション 細胞賦活化剤
JP2020127398A (ja) * 2019-02-07 2020-08-27 株式会社神鋼環境ソリューション サーチュイン発現量増進剤

Also Published As

Publication number Publication date
JPWO2023149408A1 (enExample) 2023-08-10

Similar Documents

Publication Publication Date Title
EP3275999B1 (en) Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method
WO2007148739A1 (ja) 植物由来の細胞賦活化剤、抗老化剤及び細胞外マトリックス産生促進剤
CN104922171A (zh) 红藜萃取物用于制备促进胶原蛋白生成及抗皮肤老化的组合物的用途
EP1813309A1 (en) Abnormal protein removing composition
EP1945046A1 (fr) Procede d'obtention d'un extrait vegetal de fruits a pepins, extrait vegetal ainsi obtenu et ses utilisations
CN1392776A (zh) 含有鞘糖脂的功能性食品或化妆品及其制造方法
JP6941746B1 (ja) 免疫賦活用食品組成物及び免疫賦活剤
JP7016983B1 (ja) Ｇｌｓ１遺伝子阻害用化粧料組成物、ｇｌｓ１遺伝子阻害剤、老化細胞除去用化粧料組成物及び老化細胞除去剤
KR101648148B1 (ko) 그라비올라 발효액을 유효성분으로 하는 피부 주름개선용 화장료 조성물 및 그의 제조방법
JP2011190217A (ja) ヒト皮膚表皮細胞増殖促進剤、それを含む皮膚外用組成物および化粧料
WO2018124002A1 (ja) プロテインｌ－イソアスパラギン酸メチルトランスフェラーゼ活性化用組成物
JP2016034910A (ja) サイトケラチン増加作用を呈するカロチノイド誘導体及びその製造方法
WO2023149408A1 (ja) 化粧料組成物、表皮角化細胞増殖用化粧料組成物、表皮角化細胞増殖剤、抗酸化剤、毛乳頭細胞増殖用化粧料組成物、毛乳頭細胞増殖剤、育毛剤、ロリクリン遺伝子発現促進剤、ヘムオキシゲナーゼ－１遺伝子発現促進剤及びコーニファイドエンベロープ形成促進剤
JP2002284632A (ja) 酒粕を有効成分とするスーパーオキシドアニオン消去物質
KR101147922B1 (ko) 화장료 조성물 및 피부 미용 식품
JP4083111B2 (ja) β−エンドルフィン産生促進剤
JP2019085331A (ja) コラーゲンのサッカロミセス属酵母発酵液を含有する皮膚外用剤
JP2023003173A (ja) 抗老化用組成物
JP2008013531A (ja) コラーゲン産生促進剤及びそれを含む美容用飲食品
JP7781388B2 (ja) 時計遺伝子発現調整用食品組成物、時計遺伝子発現調整用化粧料組成物、時計遺伝子発現調整剤、体内時計調整用食品組成物、体内時計調整用化粧料組成物、体内時計調整剤、概日リズム調整用食品組成物、概日リズム調整用化粧料組成物及び概日リズム調整剤
TWI897286B (zh) 甘藷蛋白質萃取物的鳳梨酶水解產物及其製備方法與用途
JP2014058459A (ja) コラーゲン産生促進懸濁液の製造方法
WO2020203217A1 (ja) Ｌｔｂｐ－１発現促進用組成物及びｌｔｂｐ－１発現促進作用を有する物質のスクリーニング方法
JP7433628B2 (ja) 皮膚外用剤及び内用剤
KR102854836B1 (ko) 어성초 캘러스 유래 엑소좀을 유효성분으로 포함하는 피부상태 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23749724

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023578548

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23749724

Country of ref document: EP

Kind code of ref document: A1